In contrast type-B monoamine oxidase (MAO-B) inhibitors, such as rasagiline and selegiline, were developed for treatment in PD owing to their ability to inhibit dopamine metabolism, thereby increasing striatal dopamine levels25. This evidence concerns the gene MAOB and Parkinson disease.